THBS1 and neoplasm: Consistent with this, our previous investigation demonstrated that targeting TSP-1 in an orthotopic syngeneic model of metastatic peritoneal carcinomatosis triggers an anti-cancer adaptive immune response synergistic with anti–PD-1 therapy, resulting in enhanced tumor regression and reduced ascites fluid production [23].